Clinical characterization of stomatitis cases with an epithelial growth factor receptor inhibitor in metastatic colorectal cancer patients: A study of 7 cases and literature review.

Autor: Gomes-Silva W; Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil. Electronic address: wagner.wgswgs@gmail.com., Vechiato-Filho AJ; Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil., Luiz AC; Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil., Guollo A; School of Dentistry, Universidade Comunitária da Região de Chapecó - Unochapecó, Chapeco, Brazil., de Oliveira MCQ; Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil., Gomes MN; Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil., Caparelli FC; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil., Brandão TB; Dental Oncology Service, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil.
Jazyk: angličtina
Zdroj: Oral surgery, oral medicine, oral pathology and oral radiology [Oral Surg Oral Med Oral Pathol Oral Radiol] 2023 Aug; Vol. 136 (2), pp. 162-172. Date of Electronic Publication: 2023 Jan 18.
DOI: 10.1016/j.oooo.2023.01.004
Abstrakt: Objective: The aim of this study was to report a case series of patients with metastatic colorectal cancer (mCRC) undergoing panitumumab-containing regimens affected by oral lesions and to review the current literature.
Study Design: Electronic medical records of mCRC patients referred to treat mouth sores during the treatment with the anti-epithelial growth factor receptor (EGFR)-panitumumab-were retrospectively reviewed. Patients' characterization, clinical profile of oral lesions, and management outcomes were documented. Additionally, modifications or discontinuation of the antineoplastic treatment as well as the occurrence of other adverse events (AEs) were analyzed.
Results: A total of 7 patients were included. The oral lesions appeared in a median time of 10 days (range 7-11 days) after the drug administration. The median reported pain score was 5 (range 1-9), causing feeding discomfort. Oral lesions with a marked aphthous-like appearance, among others, occurred in all cases and involved nonkeratinized mucosa more likely. At least 1 patient had dose reduction of the treatment and 1 patient needed discontinuation due to panitumumab-associated stomatitis. Dermatologic AEs were the most prevalent. Clinical improvement was obtained with topical corticosteroid therapy and/or photobiomodulation.
Conclusions: In summary, panitumumab-containing regimens were associated with a particular pattern of oral lesions consistent with stomatitis. This event may eventually affect the tolerability of the treatment in patients with mCRC.
Competing Interests: Declarations of interest None.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: